Article info

Download PDFPDF

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Authors

  1. Correspondence to Professor Christian Marth, AGO-Austria and Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria; Christian.marth{at}tirol-kliniken.at
View Full Text

Citation

Marth C, Tarnawski R, Tyulyandina A, et al
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Publication history

  • Accepted October 13, 2021
  • First published November 19, 2021.
Online issue publication 
January 03, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.